Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. - Wikidata - wikimedia - TriplyDB

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

http://www.wikidata.org/entity/Q34194609

about

Advances and challenges in malaria vaccine development A review of malaria vaccine clinical projects based on the WHO rainbow table A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria Plasmodium falciparum merozoite surface protein 3: oligomerization, self-assembly, and heme complex formation A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum Malaria vaccine clinical trials: what's on the horizon Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif Duplicated paralogous genes subject to positive selection in the genome of Trypanosoma brucei Molecular Evolution of PvMSP3α Block II in Plasmodium vivax from Diverse Geographic Origins A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720 Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties.Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24 Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.Recent progress in adjuvant discovery for peptide-based subunit vaccines Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs Specific antibody responses against membrane proteins of erythrocytes infected by Plasmodium falciparum of individuals briefly exposed to malaria.Multiple antigen peptide vaccines against Plasmodium falciparum malaria Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51 Blood stage vaccines for Plasmodium falciparum: current status and the way forward.B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein Seroprevalence of malaria in inhabitants of the urban zone of Antananarivo, Madagascar.Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.Allelic Diversity and Geographical Distribution of the Gene Encoding Plasmodium falciparum Merozoite Surface Protein-3 in Thailand.Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans Antigenicity and immunogenicity of PvRALP1, a novel Plasmodium vivax rhoptry neck protein.Naturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous communities of the Venezuelan Amazon Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Design and optimization of peptide nanoparticles Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure

P2860

Q21032463-D0D66102-44FD-4956-BC9D-C361188FA223 Q21034112-89DB37E1-2127-48C5-8DD7-0E04F2B652F6 Q24814432-0D052406-A628-4A89-AA31-576F2A2F91FE Q26772878-93EDE46F-EC9D-4807-9C91-3F52720F15B6 Q27974527-E15673FE-7398-47A0-BEAA-74C484AF0EE4 Q27974528-CFD7FA89-3CE2-4AC5-95A2-90A0DCE0AC3E Q28083110-73A2767D-08C0-4639-86DD-17940311E0A6 Q28469255-A03002FF-79EF-4A14-B072-A80F03B8A248 Q28472779-FC492C29-F459-42EE-83EE-AEFCD14A74D8 Q28611284-391D9850-4509-4AF0-B061-FCB7DAB59A91 Q28744696-BEDEA80B-345F-4B91-A7FE-F37C03EE3516 Q30492536-B038399F-4F52-4AEE-8007-5C2CEC0B8812 Q33244194-FFDE2922-5D82-49F8-BD8D-C148F12CDF8C Q33305467-C9168B10-EF02-4D9C-B04D-AA561FED6BA7 Q33350210-DD8E82AE-538A-4FE0-BE92-F4DAF37BC61D Q33508230-EBB7F20E-D34B-4F5D-B4A8-4771B513CE83 Q33512533-401B659E-969A-446B-A480-A65317C62367 Q33743450-01002ADC-1125-4DF5-B9DA-F470EE9B1EE2 Q33762869-5AD9EBFB-11D9-4A1B-8D16-E8E5A85454E7 Q34033780-F7423ED7-B1AE-44E0-89E9-C13A4991AD12 Q34092432-AFFAC083-3578-4DD1-A2A4-F30C991C6780 Q34221892-4A63AF9E-147D-4C26-955E-246D14861AD7 Q34290800-00EF5D47-3CB5-4139-905B-369D288D1630 Q34546201-F190DA6F-0D17-4B44-B5E2-1D8BE4B41E91 Q34663978-E6D2F6D3-251A-4327-A9BB-850EEBAA7942 Q34726966-3AAF0F9D-5A70-4DA4-8F21-DA1CD02E345C Q34994491-AA342F91-D38C-4F04-8477-859A430A0F03 Q35157517-D436BA22-DB14-45E9-AABD-945E4ACB1A02 Q35557657-AF5D56C0-B415-45C7-9FA6-E404593C047A Q35559584-0266B531-72DE-45FE-9FA8-7F3A4C0779CD Q35586865-ECBA0AEE-66D1-4EAB-92DA-671B2EF8303C Q35619023-4F773F26-C109-41C5-A6A7-67486A4C3228 Q35812148-80417FD3-2F5A-443C-95C7-BD16ED89C9F7 Q35917797-B0261AF2-2CFD-4CED-A2B7-8F180257D906 Q35990786-6F900D54-A673-4729-82B9-3C495F469576 Q36023082-3F34A3A0-A148-4E50-93EB-D33F53E7EDC7 Q36203154-B42B90B6-1F2A-4AFD-98CA-EEE4FA72EDA2 Q36421572-F87C485D-7889-4D6F-B30F-D42F955DF2F4 Q36687352-64D89C9B-B6F7-48A8-8582-DDBF3ED16D5D Q36787510-7064A12C-366A-48E4-8B31-7E9455C04628

P2860

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

http://www.wikidata.org/entity/Q34194609

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@ast

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@en

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@nl

type

label

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@ast

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@en

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@nl

prefLabel

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@ast

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@en

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@nl

P1433

Q34194609-81C17226-16D0-44B7-B7A8-F6A85D43016E

P1476

Q34194609-AFC282B4-3F0E-4CB6-AFAC-2813899E6BAB

P2093

Q34194609-17804175-FA01-4AB9-92DB-58A1F7EDBC6F

Q34194609-52D94D33-E13F-4322-A25A-DDCF4EBB9F33

Q34194609-967EBEB5-AE29-40E4-8E33-B8698B149FEB

Q34194609-E5080E69-057C-4F76-A8B0-2015395F93CB

Q34194609-F909C205-0115-42AF-A2C8-A7B7F1E04AC5

P2860

Q34194609-00C4648D-C08F-48B3-A9F2-4ABF387C502A

Q34194609-04C4967F-AC77-4A03-87E1-4B7CCD5C4AB2

Q34194609-0D403BAE-8108-46B5-989A-75662F80808E

Q34194609-185AD142-A7A4-41F7-9879-F89EDB5E3EF7

Q34194609-2893145B-C8D1-480A-B676-9DEE0E9AF31F

Q34194609-2FDDE92F-D168-4660-8CC2-C32403BC6DFC

Q34194609-396EE199-2712-497F-ACC6-33B743973A12

Q34194609-3C5ABB29-5594-4EAE-B143-2A0AD3D99EF6

Q34194609-48B8CE42-7146-4B10-A657-2B17D36D9B6F

Q34194609-498B1219-3538-4650-83BE-FCFB4A675751

P304

Q34194609-E745D45F-7BBB-4BAB-AE80-A851819963F2

P31

Q34194609-B481C11D-5B47-4F8A-B219-2C84F1C5B5A5

P356

Q34194609-FAA38CF6-F06B-47DD-965C-E8CCA0DA4F0A

P407

Q34194609-D9C580D8-3109-4F42-BA65-D93180A7405B

P433

Q34194609-439F09BF-003B-423F-BB25-824F9B5CFC21

P478

Q34194609-A5309DAD-DAC7-4F55-B81D-5CE11D5B0BA6

P50

Q34194609-4C825777-576D-4C5E-B890-F7AF67804D9C

Q34194609-6C12F9B0-D4B4-4570-B546-B4600501CE89

Q34194609-DA6C0775-E518-40AC-8696-53C3FEA127F2

P577

Q34194609-E40B51A5-29C0-4CBB-ACE2-854F3C72A516

P5875

Q34194609-2109137C-C8F8-408A-A2C8-C56784268E76

P698

Q34194609-82E6648E-600A-464B-A9CF-9807D17158D8

P921

Q34194609-947C061D-E42F-494C-B68F-72467326E3BB

Q34194609-F3906947-5B65-4033-9AB5-7EC1B11E1533

P932

Q34194609-DA6DE960-D2D7-4A48-92D6-1116AFE8A440

P356

IAI.73.12.8017-8026.2005

P1433

Infection and Immunity

P1476

Phase I malaria vaccine trial ...... ite surface protein 3 antigen.

@en

P2093

Floriana Lurati

http://www.w3.org/2001/XMLSchema#string

François Spertini

http://www.w3.org/2001/XMLSchema#string

Michel Cachat

http://www.w3.org/2001/XMLSchema#string

Odile Leroy

http://www.w3.org/2001/XMLSchema#string

Régine Audran

http://www.w3.org/2001/XMLSchema#string

P2860

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

Aluminum salts in vaccines--US perspective

The global impact of vaccines containing aluminium adjuvants

Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studies.

Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants

Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans.

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro

Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum

Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide.

P304

8017-8026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.73.12.8017-8026.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Giampietro Corradin

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7469921

http://www.w3.org/2001/XMLSchema#string

P698

16299295

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

1307056

http://www.w3.org/2001/XMLSchema#string